Abatacept Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Rheumatoid Arthritis

IV administration:
If less than 60 kg, give 500 mg
If 60 to 100 kg, give 750 mg
If greater than 100 kg, give 1000 mg
Administer once as a 30-minute intravenous infusion. The dose is repeated 2 and 4 weeks after the initial dose, then every 4 weeks thereafter. It may be administered alone or with disease-modifying antirheumatic drugs other than TNF antagonists.

Subcutaneous administration:
After a single IV infusion as a loading dose (as per body weight categories above), 125 mg administered by subcutaneous injection should be given within a day, followed by 125 mg subcutaneously once a week.
Patients who are unable to receive an infusion may initiate weekly injections subcutaneously without an intravenous loading dose.
Patients transitioning from IV therapy to subcutaneous administration should administer the first subcutaneous dose instead of the next scheduled intravenous dose.

Usual Pediatric Dose for Juvenile Idiopathic Arthritis

Reduction of signs and symptoms in patients with moderately to severely active polyarticular juvenile idiopathic arthritis:
6 to 17 years:
If less than 75 kg, give 10 mg/kg IV
75 kg to 100 kg, give 750 mg IV
If greater than 100 kg, give 1000 mg IV

The maximum dose per intravenous administration should not exceed 1000 mg.

Administer once as a 30-minute intravenous infusion. The dose is repeated 2 and 4 weeks after the initial dose, then every 4 weeks thereafter. It may be administered alone or concomitantly with methotrexate.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

The safety and efficacy of abatacept in pediatric patients below 6 years of age have not been determined.

Dialysis

Data not available

Other Comments

Abatacept may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (DMARDs) other than tumor necrosis factor (TNF) antagonists.

If therapeutic benefit is not evident within 6 months of initiating therapy, an alternative therapy should be considered.

Abatacept must be reconstituted with 10 mL of water for injection, using only the silicone-free disposable syringe provided with each vial and an 18- to 21-gauge needle. The reconstituted solution must be further diluted with 100 mL of normal saline prior to administration.

Hide
(web3)